Isoprostane 8-epi-prostaglandin F(2α) is a potent contractor of human peripheral lymphatics

Lymphology

Volumn 30, Issue 3, 1997, Pages 155-159

  Sinzinger, Helmut ^a,b   Oguogho, A ^b   Kaliman, J ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b Wilhelm Auerswald Atherosclerosis Research Group   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 8 EPIPROSTAGLANDIN E1; 8 EPIPROSTAGLANDIN F2ALPHA; 8 ISOPROSTAGLANDIN E2; ISOPROSTANE DERIVATIVE; PROSTAGLANDIN DERIVATIVE; THROMBOXANE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH VESSEL; LYMPHATIC SYSTEM; MALE; PRIORITY JOURNAL; VASOCONSTRICTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADOLESCENT; ADULT; DINOPROST; FEMALE; HUMANS; LYMPHATIC SYSTEM; MALE; MIDDLE AGED; PROSTAGLANDIN ENDOPEROXIDES, SYNTHETIC; THROMBOXANE A2; VASOCONSTRICTOR AGENTS;

EID: 0030863607     PISSN: 00247766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sinzinger, H, J Kaliman, E Mannheimer: Arachidonic acid metabolites of human lymphatics. Lymphology 17 (1984), 39-42.
2. Moncada, S, RJ Gryglewski, S Bunting, et al: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263 (1976), 663-665.
3. Morrow, JD, TA Minton, CR Mukundan, et al: Free radical-induced generation of isoprostanes in vivo. J. Biol. Chem. 269 (1994), 4317-4326.
4. Morrow, JD, KE Hill, RF Burk, et al: A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA 87 (1990), 9383-9387.
5. Morrow, JD, TA Minton, LJ Roberts II: The F2-isoprostane, 8-epi-prostaglandin F2α, a potent agonist of the vascular thromboxane/ endoperoxide receptor, is a platelet thromboxane /endoperoxide antagonist. Prostaglandins 44 (1992), 155-163.
6. Banerjee, M, KH Kang, JD Morrow, et al: Effects of a novel prostaglandin, 8-epi-prostaglandin F2α, in rabbit lung in situ. Am. J. Physiol. 263 (1992), H660-H664.
7. Takahashi, K, TM Nammour, M Fukunaga, et al: Glomerular actions of a free radicalgenerated novel prostaglandin, 8-epi-prostaglandin F2α, in the rat. J. Clin. Invest. 90 (1992), 136-141.
8. Johnston, MG, JL Gordon: Regulation of lymphatic contractility by arachidonic acid metabolites. Nature 293 (1981), 294-297.
9. Johnston, MG, JB Hay, HZ Movat: Kinetics of prostaglandin production in various inflammatory lesions, measured in draining lymph. Am. J. Pathol. 95 (1979), 225-238.
10. Mannheimer, E, H Sinzinger, K Silberbauer: Histologie und Prostaglandine in der Lymphologie. Angio Archiv, l (1981), 19-20.
11. Sinzinger, H, J Kaliman, E Mannheimer: Regulation of human lymph contractility by prostaglandins and thromboxane. Lymphology 17 (1984), 43-45.
12. Moore, KP, V Darley-Usmar, J Morrow, et al: formation of F2-isoprostanes during the oxidation of human low-density lipoprotein by peroxynitrite. In: Advances in Prostaglandin, Thromboxane, and Leukotriene Research. Samuelsson, B, P Ramwell, R Paoletti, et al (Eds.), Raven Press, New York, Vol. 23 (1995), 225-227.
13. Longmore, AW, LL Swift, LJ Roberts II, et al: Effect of oxygen tension on the generation of F2-isoprostanes and malondialdehyde in peroxidizing rat liver microsomes. Biochem. Pharmacol. 47 (1994), 1173-1177.
14. Morrow, JD, LJ Roberts II: Quantification of non-cyclooxygenase derived prostanoids as a marker of oxidative stress. Free Radio. Biol. Med. 10(1991), 195-200.
15. Morrow, JD, TA Minton, CR Mukundan, et al: Free radical-induced generation of isoprostanes in-vivo. Evidence for the formation of D-ring and E-ring isoprostanes in-vivo. J. Biol. Chem. 269 (1993), 4317-4326.
16. Morrow, JD, TA Minton, KF Badr, et al: Evidence that the F2-isoprostane, 8-epi-prostaglandin F2α, is formed in vivo. Biochim. Biophys. Acta 1210 (1994), 244-248.
17. Yin, K, PV Halushka, Y-T Yan, et al: Antiaggregatory activity of 8-epi-prostaglandin F2α and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets. J. Pharmacol. Exp. Ther. 270 (1994), 1192-1196.
18. Morrow, JD, LJ Roberts II: The isoprostanes. Current knowledge and directions for future research. Biochem. Pharmacol. 51 (1996), 1-9.
19. Crankshaw, D: Effects of the isoprostane, 8-epi-prostaglandin F2α, on the contractility of the human myometrium in vitro. Europ. J. Pharmacol. 285 (1995), 151-158.
20. Ogletree, ML: Coronary contraction induced by 8- epiprostaglandin F2α is independent of prostaglandin F2α receptor and is mediated by thromboxane receptors. Circulation 86, Suppl. 1 (1992), 1-298.
21. Kang, HK, JD Morrow, LJ Roberts II, et al: Airway and vascular effects of 8-epi-prostaglandin F2α in isolated perfused rat lung. J. Appl. Physiol. 74 (1993), 460-465.
22. Yura, T, M Fukunaga, R Grygorczyk, et al: Molecular and functional evidence for the distinct nature of F2-isoprostane receptors from those of thromboxane A2. Adv. Prostagl. Thromboxane Leukotr. Res. 23 (1995), 237-239.
23. Mohler, ER, MT Franklin, LP Adam: Intracellular signalling by 8-epi-prostaglandin F2α is mediated by thromboxane A2/prostaglandin endoperoxide receptors in porcine carotid arteries. Biochem. Biophys. Res. Commun. 225 (1996), 915-923.
24. Fukunaga, M, K Takahashi, KF Badr: Vascular smooth muscle action and receptor interactions of 8-iso-PGE2, and E2-iso-prostane. Biochem. Biophys. Res. Commun. 195 (1993), 507-515.